WIPO logo
Mobile | Deutsch | Español | Français | 日本語 | 한국어 | Português | Русский | 中文 | العربية |
PATENTSCOPE

Search International and National Patent Collections
World Intellectual Property Organization
Search
 
Browse
 
Translate
 
Options
 
News
 
Login
 
Help
 
Machine translation
1. (WO2018089328) TREATMENT OF CNS DISEASES WITH SGC STIMULATORS
Latest bibliographic data on file with the International Bureau    Submit observation

Pub. No.:    WO/2018/089328    International Application No.:    PCT/US2017/060299
Publication Date: 17.05.2018 International Filing Date: 07.11.2017
IPC:
A61K 31/437 (2006.01), A61K 31/5025 (2006.01), A61K 31/506 (2006.01), A61K 31/519 (2006.01), A61P 25/00 (2006.01)
Applicants: IRONWOOD PHARMACEUTICALS, INC. [US/US]; 301 Binney Street Cambridge, MA 02142 (US)
Inventors: JUNG, Joon; (US).
LEE, Thomas, Wai-ho; (US).
IYENGAR, Rajesh, R.; (US).
PERL, Nicholas, Robert; (US).
GERMANO, Peter; (US).
RIBADENEIRA, Maria, D.; (US).
TANG, Kim; (US)
Agent: DAVIS, Steven, G.; (US).
BAI, Mei; (US).
BOWLES, Anita, M.; (US).
BELT, Erik, P.; (US).
BLAZESKI, George; (US)
Priority Data:
62/419,059 08.11.2016 US
Title (EN) TREATMENT OF CNS DISEASES WITH SGC STIMULATORS
(FR) TRAITEMENT DE MALADIES DU SNC AU MOYEN DE STIMULATEURS DE GCS
Abstract: front page image
(EN)The present disclosure relates to the use of stimulators of soluble guanylate cyclase (sGC), pharmaceutically acceptable salts thereof and pharmaceutical formulations or dosage forms comprising them, alone or in combination with one or more additional agents, for the treatment of various CNS diseases, wherein an increase in sGC stimulation, or an increase in the concentration of nitric oxide (NO), or cyclic guanosine 3',5'-monophosphate (cGMP) or both, or an upregulation of the NO pathway is desirable.
(FR)La présente invention concerne l'utilisation de stimulateurs de guanylate cyclase soluble (GCs), des sels pharmaceutiquement acceptables de ceux-ci et des formulations pharmaceutiques ou des formes posologiques les comprenant, seuls ou en combinaison avec un ou plusieurs agents supplémentaires, pour le traitement de diverses maladies du système nerveux central (SNC), une augmentation de la stimulation de GCs, ou une augmentation de la concentration en oxyde nitrique (ON), ou guanosine 3',5'-monophosphate cyclique (GMPc) ou les deux, ou une régulation à la hausse de la voie de ON est souhaitable.
Designated States: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.
African Regional Intellectual Property Organization (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW)
Eurasian Patent Organization (AM, AZ, BY, KG, KZ, RU, TJ, TM)
European Patent Office (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR)
African Intellectual Property Organization (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).
Publication Language: English (EN)
Filing Language: English (EN)